Keywords: بعد از; dose escalation; dose optimization; psoriasis; secukinumab; AE; adverse event; PASI; Psoriasis Area and Severity Index; PASI-75; 75% reduction from baseline PASI score; PGA; Physician Global Assessment;
مقالات ISI بعد از (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بعد از; Psoriatic arthritis; Anti-CarP antibody; PASI; Ultrasound;
Keywords: بعد از; ADA; anti-drug antibody; nADA; neutralizing anti-drug antibody; PASI; Psoriasis Area and Severity Index; PK; pharmacokinetics; Q2W; every 2 weeks; Q4W; every 4 weeks; TE-ADA; treatment-emergent anti-drug antibody;
Keywords: بعد از; 4PL; 4 parameters logistic regression; DEGs; Differentially expressed genes; ELISA; Enzyme-linked immunosorbent assays; FC; Fold change; GEO; Gene Expression Omnibus; LC/GC-MS; Liquid chromatography/Gas chromatography-mass spectrometry; PASI; Psoriasi
Keywords: بعد از; FCH; fold change; FDR; false discovery rate; GSVA; gene-set variation analysis; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; TH17; T helper type 17; TNF; tumor necrosis factor; TRANCE; tumor necrosis factor-related activation-induced cyto
Keywords: بعد از; ISS; itch severity scale; NRS; numeric rating scale; PASI; Psoriasis Area and Severity Index; QoL; quality of life; VAS; visual analog scale;
Keywords: بعد از; 4 years; interleukin 17; ixekizumab; long-term; open-label; psoriasis; BCC; basal cell carcinoma; DLQI; Dermatology Life Quality Index; HADS; Hospital Anxiety and Depression Scale; IBD; inflammatory bowel disease; IL; interleukin; LOCF; last observation c
Keywords: بعد از; PASI; Psoriasis Area and Severity Index; IL; interleukin; fzd; frizzled receptors; IFN; interferon; ADAM; a disintegrin and metalloproteinase; EGF; epidermal growth factor; TGF; transforming growth factor; TPA; 12-o-tetradecanoyl phorbol-13-acetate; VEGF;
Keywords: بعد از; enthesitis; nail; onycholysis; psoriatic arthritis; splinter hemorrhage; transverse grooves; CI; confidence interval; DIP; distal interphalangeal; NAPSI; Nail Psoriasis Severity Index; OR; odds ratio; PASI; Psoriasis Area and Severity Index; PsA; psoriati
Keywords: بعد از; discontinuation; methotrexate; moderate-to-severe psoriasis; Psoriasis Area and Severity Index (PASI); prediction; response; AUC; area under the curve; DLQI; Dermatology Life Quality Index; ITT; intent-to-treat; PASI; Psoriasis Area and Severity Index; PA
Keywords: بعد از; psoriasis; psychodermatology; quality of life; skin lesions; social rejection; social stigma; stigmatization; DLQI; Dermatology Life Quality Index; FSQ; Feelings of Stigmatization Questionnaire; HRQoL; health-related quality of life; PASI; Psoriasis Area
Keywords: بعد از; ACR; American College of Rheumatology; bDMARDs; biologic disease-modifying antirheumatic drugs; DMARDs; disease-modifying antirheumatic drugs; EULAR; European League Against Rheumatism; GRAPPA; Group for Research and Assessment of Psoriasis and Psoriatic
Keywords: بعد از; AUC; area under the receiver operating characteristic curve; PASI; Psoriasis Area and Severity Index; PASI75; at least 75% reduction in Psoriasis Area and Severity Index score; UPSC; universal psoriasis skin classifier;
Keywords: بعد از; Acitretin (PubChem CID:5284513); Methotrexate (PubChem CID:126941); DLQI; dermatology life quality index; ELISA; enzyme linked immunosorbent assay; IL; interleukin; PASI; psoriasis area and severity index; qRT-PCR; quantitative real-time polymerase chain
Keywords: بعد از; AD; atopic dermatitis; α2HS-GP; alpha-2-HS-glycoprotein; CCL20; C-C motif ligand 20; CCR2; C-C chemokine receptor type 2; CRP; C-reactive protein; CYA; ciclosporin; DC; dendritic cells; Dkk-1; dickkopf-related protein 1; dMVECs; dermal microvascular
Keywords: بعد از; APC; antigen presenting cell; DLS; dynamic light scattering; PFA; paraformaldehyde; COX; cycloxygenase; LOX; lipoxygenase; LPS; lipo poly saccharide; FBS; fetal bovine serum; IMQ; imiquimod; SOD; superoxide dismutase; MDA; malon di-aldehyde; GSH; glutathi
Keywords: بعد از; CI; confidence interval; DLQI; dermatology life quality index; NMA; network meta-analysis; PASI; psoriasis area and severity index; RCT; randomized controlled trial; SUCRA; surface under the cumulative ranking curve;
Keywords: بعد از; biological therapy; psoriasis; ustekinumab; ADA; antidrug antibodies; DLQI; Dermatology Life Quality Index; PASI; Psoriasis Area and Severity Index;
Keywords: بعد از; apremilast; cost per responder; cost-effectiveness; indirect comparison; methotrexate; moderate to severe psoriasis; number needed to treat; Psoriasis Area and Severity Index; AAD; American Academy of Dermatology; CI; confidence interval; FDA; Food and Dr
Keywords: بعد از; etanercept; long-term safety; open-label; pediatric population; plaque psoriasis; AE; adverse event; CDC; Centers for Disease Control and Prevention; FDA; Food and Drug Administration; HRQOL; health-related quality of life; JIA; juvenile idiopathic arthri
Keywords: بعد از; Dermatology Life Quality Index; health-related quality of life; patient-reported outcomes; plaque psoriasis; Psoriasis Area and Severity Index; Psoriasis Symptom Inventory; static Physician Global Assessment; DLQI; Dermatology Life Quality Index; HRQoL; h
Keywords: بعد از; PASI; psoriasis area and severity index; AICAR; 5-aminoimidazole-4-carboxamide ribonucleotide; APCP; α,β-methylene adenosine-5â²-diphosphate; IL; interleukin; CVD; cardiovascular disease; DC; dendritic cell; Methotrexate; Psoriasis; Psoriatic arthritis
Keywords: بعد از; Psoriasis; Inflammation; Obesity; n-3 Polyunsaturated fatty acids; n-6 Polyunsaturated fatty acids; Diet therapy; AA; arachidonic acid; AHA; American Heart Association; ALA; alpha-linolenic acid; DGLA; dihomo-gamma-linolenic acid; DHA; docosahexaenoic aci
Keywords: بعد از; diet; fish oil; nutrition; omega-3; oral vitamin D; psoriasis; selenium; vitamin B12; 1,25-dihydroxycholecalciferol; 1,25-dihydroxyvitamin D3; 1,25-(OH)2D3; DHA; docosahexaenoic acid; EPA; eicosapentaenoic acid; PASI; Psoriasis Area Severity Index; UV; ul
Keywords: بعد از; Psoriasis; Comorbilidades; Criterios de gravedad: BSA; Body Surface Area; PASI; Psoriasis Area and Severity Index; DLQI; Dermatology Life Quality Index; Fototerapia; Retinoides; Metotrexato; Ciclosporina; Terapia biológica;
Keywords: بعد از; chronic urticaria; diet; melanoma; nutrition; psoriasis; DLQI; Dermatology Life Quality Index; EGCG; epigallocatechin-3-gallate; IgE; immunoglobulin E; PASI; Psoriasis Area and Severity Index; PUFA; polyunsaturated omega-3 fatty acid; RCT; randomized, con
Keywords: بعد از; Beau lines; epidemiology; leukonychia; nail psoriasis; Nail Psoriasis Severity Index; nails; onycholysis; psoriasis; splinter hemorrhages; NAPSI; Nail Psoriasis Severity Index; PASI; Psoriasis Area and Severity Index; PsA; psoriatic arthritis;
Keywords: بعد از; Dermatology; Psoriasis; Stratification; CAD system; PASI; Area; Erythema; Scaliness; Thickness
The expression of mCTLA-4 in skin lesion inversely correlates with the severity of psoriasis
Keywords: بعد از; CTLA4; Cytotoxic T lymphocyte antigen-4; sCTLA-4; soluble Cytotoxic T lymphocyte antigen-4; mCTLA-4; membrane Cytotoxic T lymphocyte antigen-4; IOD; Integrated option density; IMQ; Imiquimod; PASI; psoriasis area and severity index; Treg; regulatory T; CT
Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges
Keywords: بعد از; ACR; American College of Rheumatology; ADAb; anti-drug antibody; ADCC; antibody-dependent cell-mediated cytotoxicity; AIFA; Italian Medicines Agency; CDC; complement-dependent cytotoxicity; CHMP; Committee for Medicinal Products for Human Use; DAS28; 28-j
Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways
Keywords: بعد از; Resolvin D1; Keratinocyte; Psoriasis; Inflammation; MAPKs; Boc; tert-butoxycarbonyl Met-Leu-Phe peptide; GAPDH; glyceraldehyde-3-phosphate dehydrogenase; IL-17; interleukin-17; IL-22; interleukin-22; IL-23; interleukin-23; IMQ; imiquimod; MAPKs; mitogen-a
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
Keywords: بعد از; AE; adverse event; BADBIR; British Association of Dermatologists Biologic Interventions Register; CI; confidence interval; HR; hazard ratio; PASI; Psoriasis Area and Severity Index; TNFI; tumor necrosis factor inhibitors;
Emerging therapies for atopic dermatitis: JAK inhibitors
Keywords: بعد از; atopic dermatitis; baricitinib; eczema; JAK inhibitor; ruxolitinib; systemic therapy; tofacitinib; CPK; creatine phosphokinase; Cr; creatinine; EASI; Eczema Area and Severity Index; JAK; Janus kinase; PASI; Psoriasis Area and Severity Index; STAT; signal
Microbe-Dependent Induction of IL-9 by CLA+ T Cells in Psoriasis and Relationship with IL-17A
Keywords: بعد از; ASO; anti-streptolysin O; CA; Candida albicans; CLA; cutaneous lymphocyte-associated antigen; CLA-/Epi; co-cultures of CLA- T cells and autologous epidermal cells; CLA+/Epi; co-cultures of CLA+ T cells and autologous epidermal cells; DC; dendritic cel
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Keywords: بعد از; cumulative benefit; itching; pain; psoriasis; quality of life; scaling; secukinumab; AUC; area under the curve; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-related quality of life; MCID; minimal clinically important differ
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Keywords: بعد از; biologic therapy; effectiveness; psoriasis; real-world; registry; safety; systemic therapy; BSA; body surface area; BMI; body mass index; DLQI; Dermatology Life Quality Index; EQ-5D; Euro-QoL-5 Dimensional; EQ-5D-3L; Euro-QoL-5 Dimensional-3 Level; IGA; I
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
Keywords: بعد از; anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPASI-1; CIMPASI-2; phase 3 trial; CZP; certolizumab pegol; DLQI; Dermatology Life Quality Index; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index;
Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48Â weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)
Keywords: بعد از; anti-TNF; anti-tumor necrosis factor; certolizumab pegol; chronic plaque psoriasis; CIMPACT; etanercept; phase 3 trial; CZP; certolizumab pegol; FcRn; neonatal Fc receptor; PASI; Psoriasis Area and Severity Index; PASI 50; â¥50% reduction in PASI from
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Keywords: بعد از; anti-IL-17; anti-IL-17A; anti-IL-17F; bimekizumab; biologic therapy; clear or almost clear skin; dose ranging; efficacy; interleukin 17A; interleukin 17F; PASI90; PASI100; phase 2b; plaque psoriasis; randomized clinical trial; safety; AE; adverse event; I
Myeloid but not plasmacytoid blood DCs possess Th1 polarizing and Th1/Th17 recruiting capacity in psoriasis
Keywords: بعد از; mDCs/pDCs/DDCs; myeloid/plasmacytoid/dermal dendritic cells; IL; interleukin; IFNα; interferon alpha; TNFα; tumor necrosis factor alpha; iNOS; inducible nitric oxide synthase; PASI; Psoriasis Area and Severity index; PBMCs; peripheral blood mononuclear
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Keywords: بعد از; clear or almost clear skin; clinical trial; phase 3; prospective; scalp psoriasis; secukinumab; Psoriasis Scalp Severity Index; AEs; adverse events; BSA; body surface area; CI; confidence interval; IGA mod 2011; Investigator's Global Assessment modified 2
Investigating the potential of Oxymatrine as a psoriasis therapy
Keywords: بعد از; Psoriasis; Oxymatrine; Hyperproliferation; Keratinocytes; OMT; Oxymatrine; HK; human skin keratinocytes; UVB; Ultraviolet B; PASI; Psoriasis Area Severity Index; SFM; serum-free media; FG; Full Green's medium; BrdU; Bromodeoxyuridine; 3-D; three-dimension
Formula PSORI-CM01 inhibits the inflammatory cytokine and chemokine release in keratinocytes via NF-κB expression
Keywords: بعد از; PSORI-CM01; formula PSORI-CM01; PCM01CS; serum contained PSORI-CM01; IMQ; imiquimod; PASI; Psoriasis Area Severity Index; IFN-γ; interferon-γ; HE; Hematoxylin and eosin; IL-6; interleukin 6; IL-8; interleukin 8; IL-12; interleukin 12; IL-17; interleukin
Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris
Keywords: بعد از; Tfh Cells; T follicular helper (Tfh) cells; PASI; psoriasis area and severity index; PV; psoriasis vulgaris; HC; healthy controls; SLE; systemic lupus erythaematosus; GC; germinal centre; PBMCs; peripheral blood mononuclear cells; PE; phycoerythrin; FITC;
Imiquimod induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipideamia comorbidity
Keywords: بعد از; ApoE; apolipoprotein E; IMQ; imiquimod; TC; total cholesterol; TG; triglycerides; LDL; low density lipoproteins; HDL; high density lipoproteins; PASI; psoriasis area and severity index; PPARs; peroxisome proliferator activated receptors; IL; interleukin;
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Keywords: بعد از; ABP 501; adalimumab; biosimilar; efficacy; equivalence; psoriasis; safety; ADA; antidrug antibody; CI; confidence interval; PASI; Psoriasis Area and Severity Index; PASI 50; 50% or more improvement in Psoriasis Area and Severity Index score from baseline;
Blood to skin recirculation of CD4+ memory T cells associates with cutaneous and systemic manifestations of psoriatic disease
Keywords: بعد از; PBMC; peripheral blood mononuclear cells; TCM; central memory T cells; TEM; effector memory T cells; TEFF; effector T cells; PASI; Psoriasis Area and Severity Index; CRP; C-reactive protein; CLA; cutaneous lymphocyte-associated antigen; Th1; T helper 1 ce
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-
Keywords: بعد از; adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; f-PGA; Fingernail Physician Global Assessment; HRQoL; health-relate
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Â year: Results from the CLEAR study
Keywords: بعد از; psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As
Bath-PUVA therapy improves impaired resting regulatory T cells and increases activated regulatory T cells in psoriasis
Keywords: بعد از; aTreg; activated regulatory T cells; Foxp3; forkhead-box p3; IL; interleukin; non-Treg; non-suppressive regulatory T cells; PASI; Psoriasis Area and Severity Index; PUVA; psoralen plus ultraviolet light A; rTreg; resting regulatory T cells; Th17; interleu